



Sources, Transport, Exposure & Effects of PFASs
UNIVERSITY OF RHODE ISLAND SUPERFUND RESEARCH PROGRAM

PFAS Mixtures & Liver Adverse Outcomes: Finding PFAS Bad Actors

Angela Slitt, B.S., Ph.D.
Professor, College of Pharmacy, URI
URI-STEEP Superfund Center



Perfluoroalkyl substances (PFASs) and concerns




- Highly persistent in environment
- Long half-lives, especially for PFOA, PFOS, and PFHxS
- 7000+ PFAS – how do we assess safety? Toxicokinetics?
- The mechanisms that dictate tissue distribution, clearance, and half-life are not well understood – even for PFOA and PFOS.
 - Highly absorbed, yet slowly eliminated
 - Cross placental barrier, detectable in breast milk
- Do not occur individually. We are exposed to complex mixtures, which are challenging to recapitulate.



PFAS	Half-life in Humans
PFBS	665 hours (3)
PFHxS	8.5 years (1)
PFOS	5.4 years (1)
PFBA	81 hours (2)
PFHxA	32 days (5)
PFHpA	1.2 years (4)
PFOA	3.8 Years (1)
PFNA	4.3 years (4)
PFDA	12 years (4)
PFUnDA	12 years (4)
PFDoDA	Unknown
PFPPrOPrA	Unknown




Emerging PFAS are also detected in pilot whale liver and livers of juvenile marine birds



Robuck, A. R. Et al., (2020). 54(20), 12938–12948.
<https://doi.org/10.1021/acs.est.0c01951>


PFAS Effects and Liver

- Liver is the tissue that often is for distribution and accumulation. Relatively high concentrations, likely due to transporters and high tissue binding.
- Associations with slight elevation in serum liver enzymes (multiple studies – human and rodent).
- Rodents demonstrate hepatomegaly (liver enlargement and cancer). This endpoint is widely debated about relevance to humans because of species differences in PPAR-alpha signaling.
- Liver is a depot for **multiple** PFAS. In humans, ~400 ng/g PFOA and ~600 ng/g PFHpA observed in livers from residents of Catalonia, Spain.
- *Little is known about PFAS mixture and adverse liver effects.*



Some PFAS Increase Risk Liver Injury and Steatosis


- Non-alcoholic fatty liver disease (NAFLD) is a rising health issue globally. Aside from potential damage to the liver, hepatic steatosis and NAFLD can increase risk for cardiovascular disease.
- Epidemiological data has found positive associations between PFOS and PFOA and biomarkers of liver injury^{1,2,3,4}.
- It is unclear if the liver diseases occur in humans, but associated with elevated markers for liver injury.
- Positive associate of PFAS association with CK18 (marker for NASH).
- Rodent models illustrate increased steatosis with PFOA, PFOS at high doses (> 1mg/kg) and increased liver injury.
- Higher PFAS exposure was associated with more severe disease in children with NAFLD⁸
- Little is known about how maternal exposure can affect liver outcomes, but higher exposure to PFAS during pregnancy has been associated with higher liver enzyme levels in children⁹



1. Gallo et al, *Environ Health Perspect*, 2012, 120(5); 655-661
2. Gleason et al. *Environ Res* 2015; 136, 8–14.
3. Lin et al. *Am J Gastroenterol*. 2010;105(6):1354-1363.
4. Darrow et al, *Environ Health Perspect*. 2016 Aug; 124(8): 1227–1233.


5. Butenhoff et al *Toxicology*. 2012;293, 1–15.
6. Botelho et al. *Chemosphere* 2015;129, 225–231.
7. Seacat et al, *Toxicol Sci*. 2002, 68(1):249-64.
8. Jin R et al., *Environ Int*. 2020 Jan;134:105220. doi: 10.1016/j.envint.2019.105220.
9. Stratakis et al., *Hepatology*, 2020, 72(5):1758-1777

Mechanisms of steatosis



Hypotheses

- ✓ PFAS mixtures will act synergistically to induce steatosis
- ✓ Maternal consumption of a high fat diet in combination with PFAS will induce adverse liver outcomes in pups



PFAS x PFAS (PxP) Interaction




Diet x Exposure (DxE) Interactions

Testing PFAS in Human Hepatocytes



Cryostax 5-donor hepatocytes



24h


Treatment with:
DMSO (vehicle), various PFAAs and mixtures of PFAAs at concentrations of 0.25 μ M to 25 μ M with daily media changes of treatments.

48h


72h

Gene expression analysis


Stain Nile-red



Targeted gene array from Invitrogen for 35 genes related to lipid and Drug metabolism




PFASs Induce Lipogenic Gene Expression in Human Hepatocytes



✓ Shorter chain PFAAs generally had a greater induction than long chain PFAAs at lower concentrations in both sulfonates and carboxylic acids

Marques et al., *Toxicol. Appl. Pharmacol.*, 2022


PFASs are capable of inducing lipid accumulation in human hepatocytes



- ✓ Only short chain PFAAs (except PFDA) induced liver lipid accumulation in our assays.
- ✓ Lipid accumulation is limited by glucose content in the media


Testing PFAS mixtures at health advisory levels

- Mix data suggested that the concentrations were too high or perhaps the PFAS negate each other's effects.
- Ultra low (pM) to high concentrations (um)
- Stack the treatments
- Selected PFAS commonly detected in Rhode Island drinking water and Cape Cod private well water.



Additive effects are observed at exposure relevant concentrations in Human Hepatocytes


- Cryopreserved human hepatocytes. 70 pM-70 μM
- Treated 6 hours after plating (vs. ~16 hours)
- Treated for 48 hrs total
- Gene expression occurred at changes at 70 pM
- Gene expression changes were observed at 70 pM but not at 70 nM or μM.
- Strong activity for PFHxS



Conclusions – *In Vitro*

- PFHxS has the potential to be transcriptionally active in cryopreserved human hepatocytes and at exposure-relevant media concentrations.
- There is potential additivity at very low PFAS concentrations (pM)
- Human hepatocyte culture conditions seems to be important for detecting PFAS activity.

An in vivo approach to mixtures





Study Design



**Timed-pregnant
Dams arrive (GD1)**
Assign Treatment groups
(n=5)

**Birth
GD18 or 19
PND 0**


**PND 21
Euthanize
dams and pups**




**Dam Treatments:
(oral gavage)**

- Veh: 0.5% Tween 20
- PFOA- 1 mg/kg
- PFOS- 1 mg/kg
- PFHxS- 1 mg/kg
- PFAS mix

PFAS mix (1:1:1):
1 mg/kg of each
PFOA
PFOS
PFHxS



PFAS concentrations in Dams



PFHxS > PFOA > PFOS

HFD vs. SD

PFOS 7.32 ug/ml ± 0.82 vs. 9.84 ug/ml ± 0.61* 

PFOA 115.2 ug/ml ± 09.23 vs. 139.2 ug/ml ± 8.43

PFHxS 212.9 ug/ml ± 16.2 vs. 225.6 ug/ml ± 25.2


PFAS Mix versus PFAS

PFOS

SD and HFD 

PFAS concentrations in PND21 Offspring Liver

PFOA > PFHxS > PFOS



HFD vs. SD

PFOS ↔

PFOA ↑


PFHxS ↔

PFAS Mix versus PFAS

PFOS

SD ↓

Dam and Pup Liver Weights



- PFOA and PFAS mix treatments increased liver weights in pups

* = $p < 0.05$ versus SD+Veh



= $p < 0.05$ versus HFD+Veh

§ = $p < 0.05$ versus PFOA and PFAS mix within each diet

‡ = $p < 0.05$ versus PFOS and PFAS mix within each diet

† = $p < 0.05$ versus PFHxS and PFAS mix within each diet

The PFAS mix increased liver total lipid content and TAGs in pup livers



- Livers of HFD-PFAS mix offspring had the highest total lipid content
- SD-PFOA, -PFOS, and -PFHxS offspring had higher livers TAGs, which was not observed in the HFD offspring
- HFD-PFAS mix offspring had the highest liver TAGs

* = p<0.05 versus SD+Veh


= p<0.05 versus HFD+Veh

§ = p<0.05 versus PFOA and PFAS mix within each diet


‡ = p<0.05 versus PFOS and PFAS mix within each diet

† = p<0.05 versus PFHxS and PFAS mix within each diet


PFAS Mix increased hepatic steatosis in pups




HFD + Veh





HFD + PFAS Mix



PFOA and PFAS Mix markedly shift the proteome in offspring livers




PFOA and a PFAS Mix induce the highest number of protein changes in offspring liver




PFOA and a PFAS Mix induce the highest number of protein changes in offspring liver

- PFOA and PFAS mix increase lipid catabolism, transport, and synthesis pathways.
- PFHxS some activity
- PFOS least activity
- PFOA driver?




What were the top hits for liver proteins?

PFOA vs. STD



PFAS MIX vs. STD




Acyl-CoA thioesterase 1 (Acot 1)

Acyl-CoA thioesterase 2 (Acot 2)



Enoyl-CoA Hydratase And 3-Hydroxyacyl CoA Dehydrogenase (Ehhadh)

Brain Response Differed Significantly from Liver



- **PFHxS > PFOA > PFOS (Brain) versus PFOA > PFHxS > PFOS (liver)**
- PFOA levels increased in HFD-PFOA
- PFOA levels decreased with mix
- PFHxS unchanged with diet or PFAS mix

Unlike liver, PFHxS was the most active modulator of the brain proteome



- The largest # of protein expression changes was observed in the SD-PFAS mix offspring
- PFHxS most active
- PFOS > PFOA

Conclusions – *In Vivo*

- Maternal treatment with a PFAS Mix in combination with exposure to a high fat diet increased measures of hepatic steatosis in mice offspring.
- Diet and presence of other PFAS influenced serum and liver concentrations (very important to measure tissue concentrations!!)
- The offspring proteome was most changed by PFOA and PFAS Mix
- Brain concentrations and proteomic response differed from liver

Bad Actors??

SOME Bad Actors

- PFOA appeared to drive much of the response in liver
- PFHxS very active in human hepatocyte model

SUM Bad Actors

- We do observe examples of synergistic behavior (PFAS mix induced liver pathologies and proteome changes in offspring)
- PFAS mix seemed to shifted brain and liver proteome the most

Acknowledgments

- NIH 1P42 ES027706, URI College of Pharmacy
- URI-HARVARD STEEP SRP
 - Dr. Rainer Lohmann, URI, GSO
 - Dr. Elsie Sunderland, Harvard Univ.
 - Dr. Jiktka Becanova, URI, GSO
 - Dr. Geoff Bothun, URI, COE
- Slitt Laboratory
 - Emily Marques, Juliana Agudelo, Emily Kaye, Sadegh Modaresi, Marisa Pfohl, Nick DaSaliva
- Dr. Michael Goedken, Rutgers University
- Fatemeh Akhlaghi, URI

- Benjamin Barlock
- Rohitash Jamwal
- Dr. Sue Fenton, NIEHS



Thoughts for the PFAS field

- ❖ Cell culture conditions can be critical for evaluating PFAS
- ❖ Diet-PFAS interactions are complex
- ❖ PFAS-PFAS measures are complex. Could have PFAS-PFAS competition for certain tissues, especially at high concentrations.
- ❖ Measuring tissue concentrations is an absolute must to related to tissue outcomes.
- ❖ Robust discussion about models, concentrations, etc. needed to design experiments that are informative.
- ❖ Evidence that PFAS in a mix has more activity than the PFAS alone.

Thank You!